Original Articles
Visualizações

Arq. Bras. Oftalmol. 2025; 88 (2): 10.5935/0004-2749.2023-0229

Total: 2048

Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?

Semih Çakmak1; Gokhan Demir2; Uğur Tunç3; Elmas Yuksel Sukun4; Yusuf Berk Akbas5; Abdullah Ozkaya6; Ozgur Artunay7; Gurkan Erdogan1

DOI: 10.5935/0004-2749.2023-0229

1. Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
2. Department of Ophthalmology, Westeye Hospital, Erbil, Iraq
3. Department of Ophthalmology, Eyup State Hospital, Istanbul, Turkey
4. Alanya Training and Research Hospital, Antalya, Turkey
5. Başakşehir Çam and Sakura Training and Research Hospital, Istanbul, Turkey
6. Department of Ophthalmology, Memorial Sisli Hospital, Istanbul, Turkey
7. Beyoglu Training and Research Hospital, Istanbul, Turkey

Corresponding author

Semih Çakmak
E-mail: [email protected]

Funding: This study received no specific financial support.

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose.


Print PDF English
Open Access
Share

How to cite this article:

Çakmak S, Demir G, Tunç U, Sukun EY, Akbas YB, Ozkaya A, et al. Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?. Arq. Bras. Oftalmol. 2025;88(2):. 10.5935/0004-2749.2023-0229
Export citation